| Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action FX Vollenweider, MFI Vollenweider-Scherpenhuyzen, A Bäbler, H Vogel, ... Neuroreport 9 (17), 3897-3902, 1998 | 681 | 1998 |
| Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia D Umbricht, L Schmid, R Koller, FX Vollenweider, D Hell, DC Javitt Archives of general psychiatry 57 (12), 1139-1147, 2000 | 584 | 2000 |
| Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naıve healthy volunteers FX Vollenweider, A Gamma, M Liechti, T Huber Neuropsychopharmacology 19 (4), 241-251, 1998 | 524 | 1998 |
| The neurobiology of psychedelic drugs: implications for the treatment of mood disorders FX Vollenweider, M Kometer Nature Reviews Neuroscience 11 (9), 642, 2010 | 518 | 2010 |
| Serotonin research: contributions to understanding psychoses MA Geyer, FX Vollenweider Trends in pharmacological sciences 29 (9), 445-453, 2008 | 396 | 2008 |
| Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis FX Vollenweider, KL Leenders, C Scharfetter, P Maguire, O Stadelmann, ... Neuropsychopharmacology 16 (5), 357-372, 1997 | 385 | 1997 |
| Gender differences in the subjective effects of MDMA ME Liechti, A Gamma, FX Vollenweider Psychopharmacology 154 (2), 161-168, 2001 | 378 | 2001 |
| Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F] fluorodeoxyglucose (FDG) FX Vollenweider, KL Leenders, C Scharfetter, A Antonini, P Maguire, ... European neuropsychopharmacology 7 (1), 9-24, 1997 | 367 | 1997 |
| Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission … FX Vollenweider, KL Leenders, I Øye, D Hell, J Angst European Neuropsychopharmacology 7 (1), 25-38, 1997 | 341 | 1997 |
| A systems model of altered consciousness: integrating natural and drug-induced psychoses FX Vollenweider, MA Geyer Brain research bulletin 56 (5), 495-507, 2001 | 325 | 2001 |
| Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study F Hasler, U Grimberg, MA Benz, T Huber, FX Vollenweider Psychopharmacology 172 (2), 145-156, 2004 | 306 | 2004 |
| Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies E Studerus, M Kometer, F Hasler, FX Vollenweider Journal of psychopharmacology 25 (11), 1434-1452, 2011 | 299 | 2011 |
| Acute psychological effects of 3, 4-methylenedioxymethamphetamine (MDMA,“Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram ME Liechti, C Baumann, A Gamma, FX Vollenweider Neuropsychopharmacology 22 (5), 513-521, 2000 | 298 | 2000 |
| Psychometric evaluation of the altered states of consciousness rating scale (OAV) E Studerus, A Gamma, FX Vollenweider PloS one 5 (8), e12412, 2010 | 280 | 2010 |
| Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia K Ludewig, MA Geyer, FX Vollenweider Biological psychiatry 54 (2), 121-128, 2003 | 260 | 2003 |
| Effects of (S)-ketamine on striatal dopamine: a [11C] raclopride PET study of a model psychosis in humans FX Vollenweider, P Vontobel, I Øye, D Hell, KL Leenders Journal of psychiatric research 34 (1), 35-43, 2000 | 255 | 2000 |
| Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT 2 antagonist ketanserin in healthy humans ME Liechti, MR Saur, A Gamma, D Hell, FX Vollenweider Neuropsychopharmacology 23 (4), 396-404, 2000 | 254 | 2000 |
| 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—a PET study with [11 C] raclopride FX Vollenweider, P Vontobel, D Hell, KL Leenders Neuropsychopharmacology 20 (5), 424-433, 1999 | 253 | 1999 |
| Acute effects of lysergic acid diethylamide in healthy subjects Y Schmid, F Enzler, P Gasser, E Grouzmann, KH Preller, FX Vollenweider, ... Biological psychiatry 78 (8), 544-553, 2015 | 246 | 2015 |
| Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers D Umbricht, R Koller, FX Vollenweider, L Schmid Biological psychiatry 51 (5), 400-406, 2002 | 245 | 2002 |
Mark A GeyerProfessor of Psychiatry, University of California San DiegoVerified email at ucsd.edu
